To identify whether KCNB1 can be used as a prognostic biomarker, we correlated KCNB1 with overall survival (OS) and progression-free survival (PFS) in samples from 83 patients with primary GBM and 41 patients with grade III glioma who underwent tumor treatment in our cohort. This evidence concerns the gene KCNB1 and glioblastoma.